์ด ์„ธ์…˜์— ๋Œ€ํ•œ ๊ธฐ๋ณธ ์„ค์ •์ด ์—…๋ฐ์ดํŠธ๋˜์—ˆ์Šต๋‹ˆ๋‹ค. ๊ณ ๊ฐ๋‹˜์˜ ๊ณ„์ • ์„ค์ •์„ ์˜๊ตฌ์ ์œผ๋กœ ๋ณ€๊ฒฝํ•˜๋ ค๋ฉด ๋‚ด ๊ณ„์ •์œผ๋กœ ์ด๋™ํ•˜์„ธ์š”.
์›ํ•˜๋Š” ์ˆ˜๋ น ๊ตญ๊ฐ€ ๋˜๋Š” ์‚ฌ์šฉ ์–ธ์–ด๋ฅผ ๋‚ด ๊ณ„์ •์—์„œ ์–ธ์ œ๋“ ์ง€ ์—…๋ฐ์ดํŠธํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
> beauty2 heart-circle sports-fitness food-nutrition herbs-supplements pageview
클릭하여 iHerb 접근성 정책 보기
₩40,000 이상 주문 시 무료배송
checkoutarrow

NAD+는 정말 노화 방지에 효과가 있을까?

479,872 조회수

근거 기반

iHerb๋Š” ์—„๊ฒฉํ•œ ์†Œ์‹ฑ ๊ฐ€์ด๋“œ๋ผ์ธ์„ ์ค€์ˆ˜ํ•˜๋ฉฐ ๋™๋ฃŒ ํ‰๊ฐ€ ์—ฐ๊ตฌ, ํ•™์ˆ  ์—ฐ๊ตฌ ๊ธฐ๊ด€, ์˜ํ•™ ์ €๋„ ๋ฐ ์ €๋ช…ํ•œ ๋ฏธ๋””์–ด ์‚ฌ์ดํŠธ์—์„œ ์ž๋ฃŒ๋ฅผ ๊ฐ€์ ธ์˜ต๋‹ˆ๋‹ค. ์ด ๋ฐฐ์ง€๋Š” ํŽ˜์ด์ง€ ํ•˜๋‹จ์˜ ์ฐธ๊ณ  ๋ฌธํ—Œ ์„น์…˜์—์„œ ์—ฐ๊ตฌ, ๋ฆฌ์†Œ์Šค ๋ฐ ํ†ต๊ณ„ ๋ชฉ๋ก์„ ์ฐพ์„ ์ˆ˜ ์žˆ์Œ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

anchor-icon 목차 dropdown-icon
anchor-icon 목차 dropdown-icon

ํ•ต์‹ฌ ์š”์ 

  • NAD+(๋‹ˆ์ฝ”ํ‹ด์•„๋งˆ์ด๋“œ ์•„๋ฐ๋‹Œ ๋””๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ)๋Š” ๋ชจ๋“  ์„ธํฌ์— ์กด์žฌํ•˜๋Š” ํ•„์ˆ˜ ์ฝ”์—”์ž์ž„์œผ๋กœ, ์—๋„ˆ์ง€ ์ƒ์„ฑ, DNA ๋ณต๊ตฌ, ๊ธฐํƒ€ ์ˆ˜๋ฐฑ ๊ฐ€์ง€์˜ ๋Œ€์‚ฌ ๊ณผ์ •์— ํ•„์ˆ˜์ ์ธ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.
  • ์ค‘๋…„๊ธฐ๊ฐ€ ๋˜๋ฉด ๋…ธํ™” ๊ด€๋ จ ์—ผ์ฆ(๋…ธํ™” ์ง•ํ›„๋ฅผ ์œ ๋ฐœ)์œผ๋กœ ์ธํ•ด NAD+ ์ˆ˜์น˜๊ฐ€ ์ž์—ฐ์ ์œผ๋กœ ์•ฝ 50% ๊ฐ์†Œํ•ฉ๋‹ˆ๋‹ค.
  • NAD+์˜ ์ฆ๊ฐ€๋Š” ์—๋„ˆ์ง€ ๋Œ€์‚ฌ ๊ฐœ์„ , ๊ฑด๊ฐ•ํ•œ ๋…ธํ™” ์ง€์›, DNA ๋ณต๊ตฌ ๊ฐ•ํ™”, ์„ธํฌ ๊ธฐ๋Šฅ ๊ฐœ์„ ๊ณผ ๊ฐ™์€ ์ด์ ๊ณผ ๊ด€๋ จ์ด ์žˆ์Šต๋‹ˆ๋‹ค.
  • ์ƒํ™œ ์Šต๊ด€์„ ๋ฐ”๊พธ๊ฑฐ๋‚˜ ํŠน์ • ์‹ํ’ˆ์„ ์„ญ์ทจํ•˜๊ณ  NMN ๋ฐ NR๊ณผ ๊ฐ™์€ NAD+ ์ „๊ตฌ์ฒด๋ฅผ ๋ณด์ถฉํ•˜๋ฉด NAD+ ์ˆ˜์น˜๋ฅผ ๋†’์ผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

โ€Œโ€Œโ€Œโ€ŒNAD+๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

NAD+(๋‹ˆ์ฝ”ํ‹ด์•„๋งˆ์ด๋“œ ์•„๋ฐ๋‹Œ ๋””๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ)๋Š” ๋ชจ๋“  ์‚ด์•„ ์žˆ๋Š” ์„ธํฌ์— ์กด์žฌํ•ฉ๋‹ˆ๋‹ค. NAD+๋Š” ๋น„ํƒ€๋ฏผB3์˜ ๊ฐ€์žฅ ํ™œ์„ฑ์ ์ธ ํ˜•ํƒœ์ž…๋‹ˆ๋‹ค. ๋‚˜์ด์•„์‹ , ๋‚˜์ด์•„์‹ ์•„๋งˆ์ด๋“œ ๊ฐ™์€ ์ผ๋ฐ˜์ ์ธ ํ˜•ํƒœ์˜ ๋น„ํƒ€๋ฏผB3๊ฐ€ ์ง€๋‚œ ์ˆ˜์‹ญ ๋…„ ๋™์•ˆ ๋ณด์ถฉ์ œ๋กœ ์‚ฌ์šฉ๋˜์–ด ์™”์ง€๋งŒ, ์ตœ๊ทผ์—๋Š” ๋ณด๋‹ค ์ƒˆ๋กญ๊ณ  ์ „๋ฌธํ™”๋œ NAD+ ์ฆ์ง„ ๋ณด์ถฉ์ œ๊ฐ€ ์„ธํฌ ๋…ธํ™”์˜ ํ•ต์‹ฌ ์š”์†Œ๋ฅผ ๋” ํšจ๊ณผ์ ์œผ๋กœ ๋ง‰์•„์ค€๋‹ค๋Š” ๊ณผํ•™์  ๊ทผ๊ฑฐ๊ฐ€ ์ ์  ๋” ์Œ“์ด๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. 

์ด๋Ÿฌํ•œ NAD+ ์ฆ์ง„ ๋ณด์ถฉ์ œ๋กœ๋Š” ๋‹ˆ์ฝ”ํ‹ด์•„๋ฏธ๋“œ ๋ชจ๋…ธ๋‰ดํด๋ ˆ์˜คํƒ€์ด๋“œ(NMN)์™€ ๊ทธ ํ™˜์› ํ˜•ํƒœ(NMNH), ๋‹ˆ์ฝ”ํ‹ด์•„๋งˆ์ด๋“œ ๋ฆฌ๋ณด์‚ฌ์ด๋“œ(NR) ๋“ฑ์ด ์žˆ์Šต๋‹ˆ๋‹ค.

NAD+๋Š” ์—๋„ˆ์ง€ ์ƒ์„ฑ, ์„ธํฌ ๋ณต๊ตฌ, ์ „์ฒด์ ์ธ ์„ธํฌ ๊ธฐ๋Šฅ ์ฆ์ง„ ๋“ฑ ๋‹ค์–‘ํ•œ ์„ธํฌ ๋Œ€์‚ฌ์— ๊ด€์—ฌํ•ฉ๋‹ˆ๋‹ค. ๋‚˜์ด์•„์‹ ์ด๋‚˜ ๋‚˜์ด์•„์‹ ์•„๋งˆ์ด๋“œ๋ฅผ ์ถฉ๋ถ„ํžˆ ์„ญ์ทจํ•ด๋„ NAD+ ์ˆ˜์น˜๋Š” ๋…ธํ™”์™€ ํ•จ๊ป˜ ๊ฐ์†Œํ•ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ ์— ์ฃผ๋ชฉํ•˜์—ฌ ๋ถ€์กฑํ•œ NAD+ ์ˆ˜์น˜๋ฅผ ํšŒ๋ณต์‹œ์ผœ ๋…ธํ™”๋ฅผ ๋ฐฉ์ง€ํ•˜๊ณ  ์„ธํฌ ๊ฑด๊ฐ•์„ ์ฆ์ง„ํ•˜๋ ค๋Š” ์ ‘๊ทผ์ด ํ•˜๋‚˜์˜ ์ „๋žต์œผ๋กœ ๋– ์˜ค๋ฅด๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

NAD+ ์ˆ˜์น˜๊ฐ€ ๋‚ฎ์•„์ง€๋ฉด ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฐ๊ณผ

NAD+๋Š” ์•„์ฃผ ์ค‘์š”ํ•œ ์„ธํฌ ๋‚ด ๋ฌผ์งˆ์ž…๋‹ˆ๋‹ค. ๋…ธํ™”์™€ ํ•จ๊ป˜ ์„ธํฌ ๊ธฐ๋Šฅ์ด ๋–จ์–ด์ง€๋Š” ์ด์œ  ์ค‘์˜ ํ•˜๋‚˜๋Š” ๋‚˜์ด๊ฐ€ ๋“ค๋ฉด์„œ NAD+ ์ˆ˜์น˜๊ฐ€ ๊ฐ์†Œํ•˜๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค. ๊ทธ ๊ฒฐ๊ณผ NAD+ ์ˆ˜์น˜๊ฐ€ ๋‚ฎ์œผ๋ฉด ๋‹ค์Œ๊ณผ ๊ฐ™์€ ์ฆ์ƒ์ด ์ƒ๊ธธ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

  • ์‹ ์ง„๋Œ€์‚ฌ ์ €ํ•˜๋กœ ์ธํ•œ ์ฒด์ค‘ ์ฆ๊ฐ€, ํ˜ˆ๋‹น ์กฐ์ ˆ ๊ธฐ๋Šฅ ๊ฐ์†Œ
  • ํ”ผ๋กœ
  • ํ˜ˆ๊ด€ ๊ฑด๊ฐ• ์ €ํ•˜
  • ๋…ธํ™”์— ๋”ฐ๋ฅธ ๊ทผ์†์‹ค(๊ทผ๊ฐ์†Œ์ฆ)
  • ๋…ธํ™”์— ๋”ฐ๋ฅธ ๊ธฐ์–ต๋ ฅ ๊ฐ์†Œ ๋ฐ ์ •์‹  ๊ธฐ๋Šฅ ์ €ํ•˜
  • ๋…ธํ™”์™€ ๊ด€๋ จ๋œ ์‹œ๋ ฅ ๋ฐ ์ฒญ๋ ฅ ์ €ํ•˜ 

NAD+๊ฐ€ ์ฒด๋‚ด์—์„œ ํ•˜๋Š” ์—ญํ• ์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

NAD+๋Š” ์šฐ๋ฆฌ ๋ชธ์˜ ๋ชจ๋“  ์„ธํฌ ์•ˆ์— ์žˆ๋Š” ์ž‘์€ ์…”ํ‹€๋ฒ„์Šค๋กœ ๋น„์œ ํ•ด ๋ณผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๊ทธ ์ฃผ๋œ ์—ญํ• ์€ '๋ณดํŽธ์  ์ „์ž ์šด๋ฐ˜์ฒด' ์—ญํ• ๋กœ์„œ, ์„ญ์ทจํ•œ ์Œ์‹์—์„œ ์ „์ž๋ฅผ ๋ฐ›์•„ ํ•„์š”ํ•œ ๊ณณ์— ์ „๋‹ฌํ•˜์—ฌ ์—๋„ˆ์ง€ ์ƒ์„ฑ์— ๊ธฐ์—ฌํ•˜๋Š” ๊ฒƒ์ž…๋‹ˆ๋‹ค. NAD+๋Š” ๋‘ ๊ฐ€์ง€ ํ˜•ํƒœ๋กœ ์กด์žฌํ•ฉ๋‹ˆ๋‹ค. NAD+๋Š” ์šดํ–‰ํ•  ์ค€๋น„๊ฐ€ ๋œ '๋นˆ' ์…”ํ‹€์ด๊ณ , NADH๋Š” ์ „์ž๋ฅผ '๊ฐ€๋“' ์‹ค์–ด ์šด๋ฐ˜ํ•˜๊ณ  ์žˆ๋Š” ์…”ํ‹€์ž…๋‹ˆ๋‹ค. ์ด ๋‘ ํ˜•ํƒœ๊ฐ€ ๋Š์ž„์—†์ด ์ „ํ™˜๋˜๋Š” ๊ณผ์ •์ด ์›ํ™œํžˆ ์ด๋ฃจ์–ด์ ธ์•ผ, ์„ธํฌ์˜ ๊ฑด๊ฐ•๊ณผ ํ™œ๋ ฅ์„ ์œ ์ง€ํ•˜๋Š” ์ˆ˜๋ฐฑ ๊ฐ€์ง€ ์ค‘์š”ํ•œ ๊ธฐ๋Šฅ์ด ์ œ๋Œ€๋กœ ์ž‘๋™ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

NAD+ ์ฆ์ง„์œผ๋กœ ์–ป์„ ์ˆ˜ ์žˆ๋Š” 7๊ฐ€์ง€ ํšจ๋Šฅ

1. ๊ฑด๊ฐ•ํ•œ ๋…ธํ™” ๋ฐ ์žฅ์ˆ˜ ์ง€์›

NAD+๋Š” ์„ธํฌ ๋…ธํ™” ๊ณผ์ •์„ ๋ง‰๋Š” ๋ฐ ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค. ์‹œ๋ฅดํˆฌ์ธ์ด๋ผ๋Š” ํŠน์ˆ˜ ๋‹จ๋ฐฑ์งˆ์„ ํ™œ์„ฑํ™”ํ•˜์—ฌ ์„ธํฌ ๋…ธํ™”๋ฅผ ์กฐ์ ˆํ•˜๊ณ  ์‹ ์ฒด์˜ ์ŠคํŠธ๋ ˆ์Šค ์ €ํ•ญ์„ ๋•์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ NAD+๋Š” ํ…”๋กœ๋ฏธ์–ด์˜ ๋‹จ์ถ•์„ ๋ง‰๋Š” ๋ฐ ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค. ํ…”๋กœ๋ฏธ์–ด๋Š” DNA๋ฅผ ๋ณดํ˜ธํ•˜๋Š” ์บก์œผ๋กœ, ์„ธํฌ๊ฐ€ ๋ถ„์—ดํ•  ๋•Œ๋งˆ๋‹ค ์ ์  ์งง์•„์ง€๋Š” ํŠน์„ฑ์ด ์žˆ์Šต๋‹ˆ๋‹ค. NAD+๋Š” ํ…”๋กœ๋ฏธ์–ด ๊ธธ์ด๋ฅผ ์œ ์ง€ํ•จ์œผ๋กœ์จ ๊ฐ ์„ธํฌ ๋‚ด์˜ ์œ ์ „์ž ์‹œ๊ณ„๋ฅผ ๋Šฆ์ถ”๋Š” ๋ฐ ๋„์›€์„ ์ค๋‹ˆ๋‹ค.

2. ์„ธํฌ ์—๋„ˆ์ง€ ์ƒ์„ฑ ์ด‰์ง„

NAD+์™€ ์ด์— ๋Œ€์‘ํ•˜๋Š” NADH๋Š” ๋ชจ๋‘ ์„ธํฌ๊ฐ€ ์—๋„ˆ์ง€๋ฅผ ์ƒ์„ฑ์‚ฐํ•˜๋Š” ๋ฐ ํ•„์ˆ˜์ ์ž…๋‹ˆ๋‹ค. ์ด๋“ค์€ ์šฐ๋ฆฌ๊ฐ€ ์„ญ์ทจํ•œ ์Œ์‹์˜ ๋ถ„์ž๋ฅผ ๋ฏธํ† ์ฝ˜๋“œ๋ฆฌ์•„(์„ธํฌ์˜ '๋ฐœ์ „์†Œ')์—์„œ ์„ธํฌ ์—๋„ˆ์ง€๋กœ ๋ฐ”๊พธ๋Š” ๋ฐ ํ•„์ˆ˜์ ์ธ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค. '์žฅ์ˆ˜ ์œ ์ „์ž'๋ผ๊ณ  ๋ถˆ๋ฆฌ๋Š” NQO1์ด๋ผ๋Š” ํŠน์ • ํšจ์†Œ๋Š” NADH์™€ ํ•จ๊ป˜ ์ž‘์šฉํ•˜์—ฌ NAD+๋ฅผ ์ƒ์„ฑํ•˜๋Š” ๋™์‹œ์—, ์„ธํฌ ์—๋„ˆ์ง€์— ์ค‘์š”ํ•œ ๋˜ ๋‹ค๋ฅธ ํ™”ํ•ฉ๋ฌผ์ธ ์ฝ”์—”์ž์ž„ Q10์˜ ํ™œ์„ฑ ํ˜•ํƒœ๋ฅผ ์žฌ์ƒํ•ฉ๋‹ˆ๋‹ค.

3. DNA ๋ณต๊ตฌ ์ง€์›

์„ธํฌ๋Š” DNA๋ฅผ ํฌํ•จํ•œ ํ•„์ˆ˜ ๋ถ„์ž๋ฅผ ๋งŒ๋“ค๊ณ  ๋ณต๊ตฌํ•˜๊ธฐ ์œ„ํ•ด NAD+์™€ NADH๊ฐ€ ๋ชจ๋‘ ํ•„์š”ํ•ฉ๋‹ˆ๋‹ค. NAD+๋Š” ๊ฒŒ๋†ˆ์˜ ์•ˆ์ •์„ฑ์„ ์œ ์ง€ํ•˜๋Š” ๋ฉ”์ปค๋‹ˆ์ฆ˜์„ ์ง€์›ํ•˜๋ฉฐ ์†์ƒ๋œ DNA๋ฅผ ๋ณต๊ตฌํ•˜๊ณ  ์„ธํฌ ๊ฑด๊ฐ•์„ ์ฆ์ง„ํ•˜๋Š” ๋ฐ ์ง์ ‘ ๊ด€์—ฌํ•˜๋Š” ์‹œ๋ฅดํˆฌ์ธ์˜ ๊ธฐ๋Šฅ์— ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.

4. ๋Œ€์‚ฌ ์ฆ์ง„

NAD+๋Š” ์ ์ ˆํ•œ ๋Œ€์‚ฌ ๊ธฐ๋Šฅ์— ํ•„์ˆ˜์ ์ž…๋‹ˆ๋‹ค. NAD+์— ์˜ํ•ด ํ™œ์„ฑํ™”๋œ ์‹œ๋ฅดํˆฌ์ธ์€ ๊ฑด๊ฐ•ํ•œ ์„ธํฌ ๋Œ€์‚ฌ๋ฅผ ์ด‰์ง„ํ•˜์—ฌ ํ˜ˆ๋‹น ์กฐ์ ˆ์„ ๊ฐœ์„ ํ•˜๊ณ  ์ฒด์ค‘์„ ๋” ์ž˜ ์กฐ์ ˆํ•  ์ˆ˜ ์žˆ๋„๋ก ๋„์™€์ค๋‹ˆ๋‹ค. ๋…ธํ™”์™€ ํ•จ๊ป˜ ๋ฐœ์ƒํ•˜๋Š” ๋‚ฎ์€ ์ˆ˜์ค€์˜ NAD+๋Š” ๋Œ€์‚ฌ ์ €ํ•˜๋กœ ์ด์–ด์ ธ ์ฒด์ค‘ ์ฆ๊ฐ€์™€ ํ˜ˆ๋‹น ์กฐ์ ˆ ์žฅ์• ๋ฅผ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

5. ๋‡Œ ๊ฑด๊ฐ• ์ฆ์ง„

๋…ธํ™”์™€ ๊ด€๋ จ๋œ ๊ธฐ์–ต๋ ฅ ๊ฐํ‡ด์™€ ์ •์‹ ๋ ฅ ๊ฐํ‡ด๋Š” NAD+ ์ˆ˜์น˜ ๊ฐ์†Œ์˜ ๊ฒฐ๊ณผ ์ค‘ ํ•˜๋‚˜์ž…๋‹ˆ๋‹ค. NR๊ณผ ๊ฐ™์€ NAD+ ์ฆ์ง„ ๋ณด์ถฉ์ œ๋ฅผ ์‚ฌ์šฉํ•œ ์ž„์ƒ์‹œํ—˜์—์„œ๋Š” ๋‹จ๊ธฐ๊ฐ„์— ์ธ์ง€ ํ…Œ์ŠคํŠธ ์ ์ˆ˜๊ฐ€ ํ–ฅ์ƒ๋˜์ง€๋Š” ์•Š์ง€๋งŒ, ๋ณด์ถฉ์ œ๋ฅผ ์„ญ์ทจํ•˜๋ฉด ๊ธฐ์–ต๋ ฅ ๋ฐ ์ธ์ง€ ๊ธฐ๋Šฅ๊ณผ ๊ด€๋ จ๋œ ๋‡Œ ์˜์—ญ์˜ ๋‡Œ ํ˜ˆ๋ฅ˜์— ๊ธ์ •์ ์ธ ๋ณ€ํ™”๋ฅผ ๊ฐ€์ ธ์˜ฌ ์ˆ˜ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

6. ํ˜ˆ๊ด€ ๊ฑด๊ฐ• ์ฆ์ง„

๋…ธํ™”์™€ ๊ด€๋ จ๋œ NAD+์˜ ๊ฐ์†Œ๋Š” ํ˜ˆ๊ด€ ๊ฑด๊ฐ• ์ €ํ•˜์™€ ๊ด€๋ จ์ด ์žˆ์Šต๋‹ˆ๋‹ค. NAD+ ์ˆ˜์น˜ ์ฆ์ง„ ๋ณด์ถฉ์ œ์ธ NR๊ณผ ๊ด€๋ จํ•œ ์—ฐ๊ตฌ์—์„œ ํ˜ˆ๊ด€ ๊ฑด๊ฐ•์€ ๊ฐ€์žฅ ์ฃผ๋ชฉ๋ฐ›๋Š” ์˜์—ญ ์ค‘ ํ•˜๋‚˜์ž…๋‹ˆ๋‹ค. ๊ณ ๋ น์ธ์„ ๋Œ€์ƒ์œผ๋กœ ์‹ค์‹œํ•œ ํ•œ ์ž„์ƒ์‹œํ—˜์—์„œ ๋งค์ผ 1,000mg์˜ NR์„ ๋ณด์ถฉํ•˜๋ฉด ๋™๋งฅ ๊ฒฝ์ง์ด ๊ฐœ์„ ๋˜๊ณ  ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••์ด ์™„๋งŒํ•˜๊ฒŒ ๊ฐ์†Œํ•˜์—ฌ ํ˜ˆ๊ด€ ์œ ์—ฐ์„ฑ ํšŒ๋ณต์— ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

7. '์—ผ์ฆ' ๋Œ€์‘

๋‚˜์ด๊ฐ€ ๋“ค๋ฉด์„œ NAD+ ์ˆ˜์น˜๊ฐ€ ๊ฐ์†Œํ•˜๋Š” ์ฃผ๋œ ์ด์œ ๋Š” '์—ผ์ฆ ๋…ธํ™”'๋กœ ์•Œ๋ ค์ง„ ๊ฐ€๋ฒผ์šด ๋งŒ์„ฑ ์—ผ์ฆ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค. ์ด ์—ผ์ฆ์€ CD38์ด๋ผ๋Š” ์„ธํฌ ํšจ์†Œ๋ฅผ ์ฆ๊ฐ€์‹œ์ผœ NAD+๋ฅผ ์ ๊ทน์ ์œผ๋กœ ๋ถ„ํ•ดํ•ฉ๋‹ˆ๋‹ค. NAD+๋ฅผ ๋†’์ด๊ณ  CD38 ํ™œ์„ฑ์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋Š” ์‹๋ฌผ์„ฑ ํด๋ฆฌํŽ˜๋†€์„ ํ™œ์šฉํ•˜๋ฉด ์—ผ์ฆ์˜ ํ•ด๋กœ์šด ์˜ํ–ฅ๊ณผ ์‹ธ์šฐ๋Š” ๋ฐ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

NMN vs. NMNH vs. NR: ๋ฌด์—‡์„ ์„ ํƒํ•ด์•ผ ํ• ๊นŒ์š”?

์‹ค์งˆ์ ์ธ ์„ ํƒ์ง€๋Š” NMN ๋Œ€ NR๋กœ ์ขํ˜€์ง‘๋‹ˆ๋‹ค. NMNH๋Š” ๊ฐ€๊ฒฉ์ด ๋น„์‹ธ๊ณ  ์‚ฌ๋žŒ์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์—ฐ๊ตฌ ์ž๋ฃŒ๊ฐ€ ๊ฑฐ์˜ ์—†๊ธฐ ๋•Œ๋ฌธ์ž…๋‹ˆ๋‹ค.

NMN๊ณผ NR ๋ชจ๋‘ NAD+ ์ˆ˜์น˜๋ฅผ ํšจ๊ณผ์ ์œผ๋กœ ๋†’์ด์ง€๋งŒ, ์—ฌ๋Ÿฌ ์ฆ๊ฑฐ์— ๋”ฐ๋ฅด๋ฉด NMN์ด ์ž„์ƒ์  ํšจ๋Šฅ์ด ๋” ์šฐ์ˆ˜ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ฃผ์š” ์ฐจ์ด์ ์€ ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค.

  • ์ „๋ฌธ๊ฐ€ ์„ ํ˜ธ๋„: ํ•˜๋ฒ„๋“œ ๋Œ€ํ•™๊ต์˜ ๋ฐ์ด๋น„๋“œ ์‹ฑํด๋ ˆ์–ด(David Sinclair) ๋ฐ•์‚ฌ๋ฅผ ๋น„๋กฏํ•œ ๋งŽ์€ ์ „๋ฌธ๊ฐ€๋“ค์ด NMN์ด ๊ฐ€์žฅ ํšจ๊ณผ์ ์ธ NAD+ ๋ถ€์Šคํ„ฐ๋ผ๊ณ  ์ƒ๊ฐํ•ฉ๋‹ˆ๋‹ค.
  • ๋ณด๋‹ค ์ง์ ‘์ ์ธ ๊ฒฝ๋กœ: NMN์€ ์‹ ์ฒด์˜ ์ƒํ•ฉ์„ฑ ๊ฒฝ๋กœ์—์„œ NAD+์— ํ•œ ๊ฑธ์Œ ๋” ๊ฐ€๊นŒ์›Œ์กŒ์œผ๋ฉฐ, ์ด๋ฅผ ์„ธํฌ๋กœ ์ง์ ‘ ์šด๋ฐ˜ํ•˜๋Š” ํŠน์ • ์ˆ˜์†ก์ฒด๊ฐ€ ํ™•์ธ๋˜์–ด ์ž ์žฌ์ ์œผ๋กœ ๊ทธ ํ™œ์šฉ๋„๊ฐ€ ํ–ฅ์ƒ๋  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
  • NR์˜ ์ž ์žฌ์  ๋‹จ์ : ๊ฒฝ๊ตฌ์šฉ NR์˜ ์ƒ๋‹น ๋ถ€๋ถ„์ด ๋‚˜์ด์•„์‹ ์•„๋งˆ์ด๋“œ๋กœ ๋ถ„ํ•ด๋˜๋Š” ๊ฒƒ์œผ๋กœ ๋ณด์ด๋ฉฐ, ์ด๋Š” NAD+ ํ•ฉ์„ฑ์„ ์†์ƒ์‹œํ‚ฌ ์ˆ˜ ์žˆ๊ณ  NR์˜ ์ผ๋ถ€ ๋…ธํ™” ๋ฐฉ์ง€ ํšจ๋Šฅ์„ ๊ฐ์†Œ์‹œํ‚ฌ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
  • ๋”์šฑ ๊ฐ•๋ ฅํ•ด์ง„ ๋™๋ฌผ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ: ์žฅ๊ธฐ๊ฐ„์˜ ์ฅ ์‹คํ—˜์—์„œ NMN ๋ณด์ถฉ์ œ๋Š” ๋‹ค์–‘ํ•œ ๊ฑด๊ฐ• ์ง€ํ‘œ๋ฅผ ๊ฐœ์„ ํ•˜๊ณ  ์ง€๊ตฌ๋ ฅ๊ณผ ์‹ ์ฒด ๋Šฅ๋ ฅ์„ ์ตœ๋Œ€ 80%๊นŒ์ง€ ์ฆ๊ฐ€์‹œํ‚ค๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋Š”๋ฐ, ์ด๋Š” NR์—์„œ๋Š” ๋ณผ ์ˆ˜ ์—†์—ˆ๋˜ ํšจ๊ณผ์ž…๋‹ˆ๋‹ค.

์„ญ์ทจ๋Ÿ‰ ๋ฐ ๋ถ€์ž‘์šฉ

์ผ๋ฐ˜์ ์œผ๋กœ NMN์€ ํ•˜๋ฃจ 250~1,000mg, NR์€ ํ•˜๋ฃจ 1,000~2,000mg์„ ์„ญ์ทจํ•ฉ๋‹ˆ๋‹ค. 

NMN ๋˜๋Š” NR์„ ๋งค์ผ ๋‘ ๋ฒˆ ์„ญ์ทจํ•˜๋Š” ๊ฒƒ์ด ์ข‹์Šต๋‹ˆ๋‹ค. ๊ณต๋ณต ์ƒํƒœ์˜ ์•„์นจ ์‹œ๊ฐ„๊ณผ ์ €๋… ์ทจ์นจ 1์‹œ๊ฐ„ ์ „์— ์„ญ์ทจํ•˜๋Š” ๊ฒƒ์ด ๊ฐ€์žฅ ์ข‹์Šต๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์šฉ๋Ÿ‰์œผ๋กœ ๋งค์ผ ์„ญ์ทจํ•˜๋ฉด ๋‚ด์•ฝ์„ฑ์ด ์ข‹์•„ ๋ถ€์ž‘์šฉ์ด๋‚˜ ์•ฝ๋ฌผ ์ƒํ˜ธ์ž‘์šฉ์ด ์ƒ๊ธฐ์ง€ ์•Š๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์Šต๋‹ˆ๋‹ค.

๊ฒฐ๋ก 

NAD+ ์ˆ˜์น˜๋ฅผ ๋†’์ด๋Š” ๊ฒƒ์€ ๊ฑด๊ฐ•ํ•œ ๋…ธํ™”๋ฅผ ์œ„ํ•œ ๊ธฐ๋ณธ ์ „๋žต์œผ๋กœ, ๋…ธํ™”์˜ ๊ฑฐ์˜ ๋ชจ๋“  ์•Œ๋ ค์ง„ ํŠน์ง•์— ๋Œ€์‘ํ•  ์ˆ˜ ์žˆ๋Š” ์ ‘๊ทผ๋ฒ•์ž…๋‹ˆ๋‹ค. DNA ๋ณต๊ตฌ์™€ ๋ฏธํ† ์ฝ˜๋“œ๋ฆฌ์•„ ์—๋„ˆ์ง€ ์ง€์›๋ถ€ํ„ฐ ์—ผ์ฆ ์กฐ์ ˆ, ์˜ค๋ž˜๋œ ์†์ƒ๋œ ์„ธํฌ ์ œ๊ฑฐ์— ์ด๋ฅด๊ธฐ๊นŒ์ง€ NAD+๋Š” ์„ธํฌ์˜ ํšŒ๋ณต๋ ฅ์„ ์œ ์ง€ํ•˜๋Š” ๋ฐ ๋งค์šฐ ์ค‘์š”ํ•ฉ๋‹ˆ๋‹ค.

์ด๋Ÿฌํ•œ ํšจ๋Šฅ์„ ๊ทน๋Œ€ํ™”ํ•˜๋ ค๋ฉด ์‹œ๋„ˆ์ง€ ํšจ๊ณผ๋ฅผ ๋‚ผ ์ˆ˜ ์žˆ๋Š” ์ ‘๊ทผ ๋ฐฉ์‹์„ ๊ณ ๋ คํ•ด ๋ณผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๊ฐ•๋ ฅํ•œ NAD+ ์ฆ์ง„ ๋ณด์ถฉ์ œ๋ฅผ ๋ ˆ์Šค๋ฒ ๋ผํŠธ๋กค ๋˜๋Š” ํ”„ํ…Œ๋กœ์Šคํ‹ธ๋ฒค๊ณผ ๊ฐ™์€ ํด๋ฆฌํŽ˜๋†€๊ณผ ํ•จ๊ป˜ ์„ญ์ทจํ•˜๋ฉด ์ด๋Ÿฌํ•œ ๊ฐ•๋ ฅํ•œ ๋…ธํ™” ๋ฐฉ์ง€ ๋ฉ”์ปค๋‹ˆ์ฆ˜์„ ๊ฐ•ํ™”ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ฐธ๊ณ ๋ฌธํ—Œ:

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021 Feb;22(2):119-141.
  2. Yaku K, Nakagawa T. NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Antioxid Redox Signal. 2023 Dec;39(16-18):1133-1149.
  3. Wang M, Cao Y, Li Y, et al. Research advances in the function and anti-aging effects of nicotinamide mononucleotide. J Zhejiang Univ Sci B. 2024 Sep 15;25(9):723-735.
  4. Biลฃฤƒ A, Scorei IR, Ciocรฎlteu MV, et al. Nicotinamide Riboside, a Promising Vitamin B3 Derivative for Healthy Aging and Longevity: Current Research and Perspectives. Molecules. 2023 Aug 15;28(16):6078.
  5. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690. 
  6. Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat Metab. 2020 Nov;2(11):1284-1304.
  7. Camacho-Pereira J, Tarragรณ MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. 
  8. Ruan Q, Ruan J, Zhang W, Qian F, Yu Z. Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty. Pharmacol Res. 2018 Feb;128:345-358.
  9. Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H. Flavonoids as inhibitors of human CD38. Bioorg Med Chem Lett. 2011 Jul 1;21(13):3939-42.
  10. Farkhondeh T, Folgado SL, Pourbagher-Shahri AM, Ashrafizadeh M, Samarghandian S. The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway. Biomed Pharmacother. 2020 Jul;127:110234. 
  11. Truong VL, Jun M, Jeong WS. Role of resveratrol in regulation of cellular defense systems against oxidative stress. Biofactors. 2018 Jan;44(1):36-49.
  12. Koushki M, Dashatan NA, Meshkani R. Effect of Resveratrol Supplementation on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther. 2018 Jul;40(7):1180-1192.e5.
  13. Marx W, Kelly JT, Marshall S, et al. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutr Rev. 2018 Jun 1;76(6):432-443. 
  14. Morifuji M, Higashi S, Ebihara S, Nagata M. Ingestion of ฮฒ-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. Geroscience. 2024 Oct;46(5):4671-4688.
  15. Yi L, Maier AB, Tao R, et al. The efficacy and safety of ฮฒ-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023 Feb;45(1):29-43. 
  16. Chen F, Zhou D, Kong AP, et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Diab Rep. 2024 Nov 12;25(1):4.https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/
  17.  Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1968-1980. 
  18. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021 Jun 11;372(6547):1224-1229.
  19. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017 Dec 6;12(12):e0186459.  
  20. Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023 Jul 21;9(29):eadi4862.
  21. Martens CR, Denman BA, Mazzo MR, Aet al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018 Mar 29;9(1):1286. 
  22. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018 Aug 1;108(2):343-353.
  23. Orr ME, Kotkowski E, Ramirez P, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience. 2024 Feb;46(1):665-682.  
  24. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell. 2005 Mar 18;17(6):855-68.
  25. Guan X, Lin P, Knoll E, Chakrabarti R. Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies. PLoS One. 2014 Sep 15;9(9):e107729.
  26. Mills KF, Yoshida S, Stein LR, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24(6):795-806. 
  27. Imai SI. NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control. NPJ Aging. 2025 Jan 27;11(1):4.

๋ฉด์ฑ…์‚ฌํ•ญ:์›ฐ๋‹ˆ์Šค ํ—ˆ๋ธŒ์˜ ์ทจ์ง€๋Š” ์˜ํ•™์ ์ธ ์ง„๋‹จ์ด๋‚˜ ์น˜๋ฃŒ๋ฅผ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์ด ์•„๋‹™๋‹ˆ๋‹ค. ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ